These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34767766)

  • 21. Ethical considerations for the modification of routine human papillomavirus immunisation schedules.
    D'Souza J; Nderitu D
    Lancet Oncol; 2022 Sep; 23(9):1121-1122. PubMed ID: 35738289
    [No Abstract]   [Full Text] [Related]  

  • 22. Prophylactic HPV vaccination for the prevention of cervical cancer.
    Hernandez BY
    Hawaii Med J; 2007 Jul; 66(7):190-1. PubMed ID: 17879858
    [No Abstract]   [Full Text] [Related]  

  • 23. When we increase fear, do we dampen hope? Using narrative persuasion to promote human papillomavirus vaccination in China.
    Liu S; Yang JZ; Chu H
    J Health Psychol; 2021 Sep; 26(11):1999-2009. PubMed ID: 31872781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved Education Should be provided to Healthcare Workers and to the Community to Increase Human Papillomavirus Vaccination Coverage in Adolescent Males.
    Marks K; Fassih S
    Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e616. PubMed ID: 34563445
    [No Abstract]   [Full Text] [Related]  

  • 25. Human papillomavirus vaccinations matter!
    van der Sande MAB; van der Loeff MFS
    Lancet Infect Dis; 2021 Oct; 21(10):1341-1342. PubMed ID: 34043962
    [No Abstract]   [Full Text] [Related]  

  • 26. Human papillomavirus vaccines.
    Satyaprakash A; Creed R; Ravanfar P; Mendoza N
    Dermatol Ther; 2009; 22(2):150-7. PubMed ID: 19335726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonavalent human papillomavirus vaccination as alternative treatment for genital warts.
    Bossart S; Gabutti MP; Seyed Jafari SM; Hunger RE
    Dermatol Ther; 2020 Jul; 33(4):e13771. PubMed ID: 32500585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan.
    Baussano I; Sayinzoga F; Tshomo U; Tenet V; Vorsters A; Heideman DAM; Gheit T; Tommasino M; Umulisa MC; Franceschi S; Clifford GM
    Emerg Infect Dis; 2021 Jan; 27(1):1-9. PubMed ID: 33350922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination for the prevention of human papillomavirus cancers.
    CA Cancer J Clin; 2020 Jul; 70(4):281-282. PubMed ID: 32639021
    [No Abstract]   [Full Text] [Related]  

  • 30. Elimination of cervical cancer depends on HPV vaccination and primary HPV screening.
    Harper DM; Jimbo M
    Lancet Infect Dis; 2021 Oct; 21(10):1342-1344. PubMed ID: 34081924
    [No Abstract]   [Full Text] [Related]  

  • 31. [Status of Human Papillomavirus Vaccination and Knowledge,Attitudes, and Influencing Factors towards Human Papillomavirus and Its Vaccines among University Students in Western China].
    Chen H; Zhou J; Huang Q; Si MY; Su XY; Li J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Aug; 43(4):545-550. PubMed ID: 34494524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do you approve of spending $300 million on HPV vaccination?: no.
    Lippman A; Boscoe M; Scurfield C
    Can Fam Physician; 2008 Feb; 54(2):175, 177, 179, 181. PubMed ID: 18272623
    [No Abstract]   [Full Text] [Related]  

  • 33. Reducing the burden of cervical cancer and HPV-related diseases through vaccination. Introduction.
    Cox JT
    Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s3-4. PubMed ID: 16520682
    [No Abstract]   [Full Text] [Related]  

  • 34. Cervical cancer: the second-generation vaccines move forward.
    Tuma RS
    J Natl Cancer Inst; 2009 Jun; 101(11):774-5. PubMed ID: 19470948
    [No Abstract]   [Full Text] [Related]  

  • 35. Human papillomavirus vaccine.
    Suba EJ; Raab SS;
    N Engl J Med; 2007 Sep; 357(11):1155; author reply 1155-6. PubMed ID: 17874469
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Brewer NT; Reiter PL
    J Natl Cancer Inst; 2010 Oct; 102(19):1517; author reply 1517-8. PubMed ID: 20811003
    [No Abstract]   [Full Text] [Related]  

  • 37. Response: Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Rozenbaum MH; Boersma C
    J Natl Cancer Inst; 2010 Mar; 102(5):358-9; author reply 359-60. PubMed ID: 20229619
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Coupé VM; Meijer CJ; Berkhof J
    J Natl Cancer Inst; 2010 Mar; 102(5):358; author reply 358. PubMed ID: 19861306
    [No Abstract]   [Full Text] [Related]  

  • 39. One in four California adolescent girls have had human papillomavirus vaccination.
    Grant D; Kravitz-Wirtz N; Breen N; Tiro JA; Tsui J
    Policy Brief UCLA Cent Health Policy Res; 2009 Feb; (PB2009-3):1-6. PubMed ID: 19288623
    [No Abstract]   [Full Text] [Related]  

  • 40. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.